AI Article Synopsis
- The study aimed to evaluate the safety and effectiveness of alfapump for controlling ascites and improving patients' quality of life.
- Results showed a significant reduction in the need for therapeutic paracentesis (TP) after implanting alfapump, with most patients experiencing over a 50% decrease in sessions.
- While some complications led to device removal, overall, the alfapump improved symptoms and physical health, suggesting it could be a viable option for patients with refractory ascites.
Article Abstract
Aim: To assess the safety and efficacy of alfapump on ascites control and quality of life in these patients.
Methods: Patients with cirrhosis and RA requiring ≥2 TPs 30 days prior were enrolled and followed for 24 months (M) post-implant. Primary efficacy endpoint assessed at 6M was reduction in paracentesis requirement; safety end point was device related adverse events resulting in intervention, explant, or death.
Results: 40 patients with RA, (mean MELD-Na: 15±4) received an alfapump. TP requirement decreased from 3.2±1.5 sessions/M pre-implant to 0.2±0.6 sessions/M at 6M post-implant (p<0.001), with 77% of patients having ≥50% reduction. Six (15%) pumps were explanted within 6M due to device related adverse events, 3 (7.5%) due to pump site skin erosion and 3 (7.5%) due to bladder discomfort. Twenty-four renal events occurred in the 0-6M post-implant period; 16 cases were readily reversible stage 1 acute kidney injury. Ascites related symptoms assessed with an Ascites Q score improved from 51.0±19.3 pre- to 32.2±21.9 at 6M post-implant (p<0.001). Physical but not mental components of Short Form 36 improved (p<0.001). The 5 deaths within 6M post-implant were not directly related to device or alfapump therapy.
Conclusions: The alfapump system effectively controlled ascites, which improved quality of life. It may be considered as an alternative to repeat TP in select patients with RA. Complication rates were similar to those expected in patients with RA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14309/ajg.0000000000003300 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of alfapump for controlling ascites and improving patients' quality of life.
- Results showed a significant reduction in the need for therapeutic paracentesis (TP) after implanting alfapump, with most patients experiencing over a 50% decrease in sessions.
- While some complications led to device removal, overall, the alfapump improved symptoms and physical health, suggesting it could be a viable option for patients with refractory ascites.
Innovative Management of a Difficult Case of Hepatic Hydrothorax.
ACG Case Rep J
June 2024
Department of Medicine, Division of Gastroenterology & Hepatology, Toronto General Hospital, University of Toronto, Toronto, Canada.
Hepatic hydrothorax affects 5%-15% of decompensated cirrhosis patients, with up to 26% being refractory to standard treatments. For those ineligible for transjugular intrahepatic systemic shunts or liver transplants, alternatives to repeated thoracentesis are limited but can include the insertion of an indwelling pleural catheter. We present the first case of the use of an automatic low-flow ascites pump (alfapump) to manage nonmalignant pleural effusion in an elderly patient with cirrhosis.
View Article and Find Full Text PDFNarrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment.
Ann Palliat Med
July 2024
Department of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Background And Objective: Malignant ascites (MA) is common in patients with advanced cancer, and about 60% of patients with MA experience distressing symptoms. In addition, MA has been identified as a poor prognostic factor, therefore, making the management of MA an important issue. We aimed to review literature describing MA provide a narrative synthesis of relevant studies.
View Article and Find Full Text PDFDaily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites.
JAMA Netw Open
July 2023
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Importance: The potential association of low-volume paracentesis of less than 5 L with complications in patients with ascites remains unclear, and individuals with cirrhosis and refractory ascites (RA) treated with devices like Alfapump or tunneled-intraperitoneal catheters perform daily low-volume drainage without albumin substitution. Studies indicate marked differences regarding the daily drainage volume between patients; however, it is currently unknown if this alters the clinical course.
Objective: To determine whether the incidence of complications, such as hyponatremia or acute kidney injury (AKI), is associated with the daily drainage volume in patients with devices.
Innovative approaches to the management of ascites in cirrhosis.
JHEP Rep
July 2023
Department of Medicine, Division of Gastroenterology & Hepatology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Standard of care for the treatment of ascites in cirrhosis is to administer a sodium-restricted diet and diuretic therapy. The progression of cirrhosis will eventually lead to the development of refractory ascites, at which point diuretics will no longer be able to control the ascites. Second-line therapies such as a transjugular intrahepatic portosystemic shunt (TIPS) placement or repeat large volume paracentesis are then required.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!